News

Endostatin may stop the progression of atherosclerosis

BMJ 1999; 318 doi: https://doi.org/10.1136/bmj.318.7190.1030b (Published 17 April 1999) Cite this as: BMJ 1999;318:1030
  1. Scott Gottlieb
  1. New York

    The experimental drug endostatin, which is being developed for its ability to shrink cancerous tumours by inhibiting the development of new blood vessels, is also showing promise in stopping atherosclerosis.

    Researchers have found that endostatin significantly reduced atherosclerosis in genetically susceptible mice. In the 16 week experiment …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe